1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Myasthenia Gravis Disease Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1.2.2 Acetylcholinesterase Inhibitors 1.2.3 Immunosuppressant Drugs 1.2.4 Steroid 1.2.5 Others 1.3 Market by Application 1.3.1 Global Myasthenia Gravis Disease Drugs Market Growth by Application: 2018 VS 2022 VS 2029 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 1.6 Years Considered 2 Global Growth Trends 2.1 Global Myasthenia Gravis Disease Drugs Market Perspective (2018-2029) 2.2 Myasthenia Gravis Disease Drugs Growth Trends by Region 2.2.1 Global Myasthenia Gravis Disease Drugs Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Myasthenia Gravis Disease Drugs Historic Market Size by Region (2018-2023) 2.2.3 Myasthenia Gravis Disease Drugs Forecasted Market Size by Region (2024-2029) 2.3 Myasthenia Gravis Disease Drugs Market Dynamics 2.3.1 Myasthenia Gravis Disease Drugs Industry Trends 2.3.2 Myasthenia Gravis Disease Drugs Market Drivers 2.3.3 Myasthenia Gravis Disease Drugs Market Challenges 2.3.4 Myasthenia Gravis Disease Drugs Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Myasthenia Gravis Disease Drugs Players by Revenue 3.1.1 Global Top Myasthenia Gravis Disease Drugs Players by Revenue (2018-2023) 3.1.2 Global Myasthenia Gravis Disease Drugs Revenue Market Share by Players (2018-2023) 3.2 Global Myasthenia Gravis Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Myasthenia Gravis Disease Drugs Revenue 3.4 Global Myasthenia Gravis Disease Drugs Market Concentration Ratio 3.4.1 Global Myasthenia Gravis Disease Drugs Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Disease Drugs Revenue in 2022 3.5 Myasthenia Gravis Disease Drugs Key Players Head office and Area Served 3.6 Key Players Myasthenia Gravis Disease Drugs Product Solution and Service 3.7 Date of Enter into Myasthenia Gravis Disease Drugs Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Myasthenia Gravis Disease Drugs Breakdown Data by Type 4.1 Global Myasthenia Gravis Disease Drugs Historic Market Size by Type (2018-2023) 4.2 Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Type (2024-2029) 5 Myasthenia Gravis Disease Drugs Breakdown Data by Application 5.1 Global Myasthenia Gravis Disease Drugs Historic Market Size by Application (2018-2023) 5.2 Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Myasthenia Gravis Disease Drugs Market Size (2018-2029) 6.2 North America Myasthenia Gravis Disease Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 6.3 North America Myasthenia Gravis Disease Drugs Market Size by Country (2018-2023) 6.4 North America Myasthenia Gravis Disease Drugs Market Size by Country (2024-2029) 6.5 United States 6.6 Canada 7 Europe 7.1 Europe Myasthenia Gravis Disease Drugs Market Size (2018-2029) 7.2 Europe Myasthenia Gravis Disease Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 7.3 Europe Myasthenia Gravis Disease Drugs Market Size by Country (2018-2023) 7.4 Europe Myasthenia Gravis Disease Drugs Market Size by Country (2024-2029) 7.5 Germany 7.6 France 7.7 U.K. 7.8 Italy 7.9 Russia 7.10 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size (2018-2029) 8.2 Asia-Pacific Myasthenia Gravis Disease Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029 8.3 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Region (2018-2023) 8.4 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Region (2024-2029) 8.5 China 8.6 Japan 8.7 South Korea 8.8 Southeast Asia 8.9 India 8.10 Australia 9 Latin America 9.1 Latin America Myasthenia Gravis Disease Drugs Market Size (2018-2029) 9.2 Latin America Myasthenia Gravis Disease Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 9.3 Latin America Myasthenia Gravis Disease Drugs Market Size by Country (2018-2023) 9.4 Latin America Myasthenia Gravis Disease Drugs Market Size by Country (2024-2029) 9.5 Mexico 9.6 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size (2018-2029) 10.2 Middle East & Africa Myasthenia Gravis Disease Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 10.3 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Country (2018-2023) 10.4 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Country (2024-2029) 10.5 Turkey 10.6 Saudi Arabia 10.7 UAE 11 Key Players Profiles 11.1 GlaxoSmithKline 11.1.1 GlaxoSmithKline Company Detail 11.1.2 GlaxoSmithKline Business Overview 11.1.3 GlaxoSmithKline Myasthenia Gravis Disease Drugs Introduction 11.1.4 GlaxoSmithKline Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.1.5 GlaxoSmithKline Recent Development 11.2 Novartis 11.2.1 Novartis Company Detail 11.2.2 Novartis Business Overview 11.2.3 Novartis Myasthenia Gravis Disease Drugs Introduction 11.2.4 Novartis Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.2.5 Novartis Recent Development 11.3 Teva Pharmaceutical 11.3.1 Teva Pharmaceutical Company Detail 11.3.2 Teva Pharmaceutical Business Overview 11.3.3 Teva Pharmaceutical Myasthenia Gravis Disease Drugs Introduction 11.3.4 Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.3.5 Teva Pharmaceutical Recent Development 11.4 Roche 11.4.1 Roche Company Detail 11.4.2 Roche Business Overview 11.4.3 Roche Myasthenia Gravis Disease Drugs Introduction 11.4.4 Roche Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.4.5 Roche Recent Development 11.5 Bristol-Myers Squibb 11.5.1 Bristol-Myers Squibb Company Detail 11.5.2 Bristol-Myers Squibb Business Overview 11.5.3 Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Introduction 11.5.4 Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.5.5 Bristol-Myers Squibb Recent Development 11.6 Apotex 11.6.1 Apotex Company Detail 11.6.2 Apotex Business Overview 11.6.3 Apotex Myasthenia Gravis Disease Drugs Introduction 11.6.4 Apotex Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.6.5 Apotex Recent Development 11.7 Cipla 11.7.1 Cipla Company Detail 11.7.2 Cipla Business Overview 11.7.3 Cipla Myasthenia Gravis Disease Drugs Introduction 11.7.4 Cipla Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.7.5 Cipla Recent Development 11.8 Biogen 11.8.1 Biogen Company Detail 11.8.2 Biogen Business Overview 11.8.3 Biogen Myasthenia Gravis Disease Drugs Introduction 11.8.4 Biogen Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.8.5 Biogen Recent Development 11.9 AbbVie 11.9.1 AbbVie Company Detail 11.9.2 AbbVie Business Overview 11.9.3 AbbVie Myasthenia Gravis Disease Drugs Introduction 11.9.4 AbbVie Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.9.5 AbbVie Recent Development 11.10 Bausch Health 11.10.1 Bausch Health Company Detail 11.10.2 Bausch Health Business Overview 11.10.3 Bausch Health Myasthenia Gravis Disease Drugs Introduction 11.10.4 Bausch Health Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.10.5 Bausch Health Recent Development 11.11 Sun Pharmaceuticals 11.11.1 Sun Pharmaceuticals Company Detail 11.11.2 Sun Pharmaceuticals Business Overview 11.11.3 Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Introduction 11.11.4 Sun Pharmaceuticals Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) 11.11.5 Sun Pharmaceuticals Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Myasthenia Gravis Disease Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029 Table 2. Key Players of Acetylcholinesterase Inhibitors Table 3. Key Players of Immunosuppressant Drugs Table 4. Key Players of Steroid Table 5. Key Players of Others Table 6. Global Myasthenia Gravis Disease Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029 Table 7. Global Myasthenia Gravis Disease Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 8. Global Myasthenia Gravis Disease Drugs Market Size by Region (2018-2023) & (US$ Million) Table 9. Global Myasthenia Gravis Disease Drugs Market Share by Region (2018-2023) Table 10. Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million) Table 11. Global Myasthenia Gravis Disease Drugs Market Share by Region (2024-2029) Table 12. Myasthenia Gravis Disease Drugs Market Trends Table 13. Myasthenia Gravis Disease Drugs Market Drivers Table 14. Myasthenia Gravis Disease Drugs Market Challenges Table 15. Myasthenia Gravis Disease Drugs Market Restraints Table 16. Global Myasthenia Gravis Disease Drugs Revenue by Players (2018-2023) & (US$ Million) Table 17. Global Myasthenia Gravis Disease Drugs Market Share by Players (2018-2023) Table 18. Global Top Myasthenia Gravis Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myasthenia Gravis Disease Drugs as of 2022) Table 19. Ranking of Global Top Myasthenia Gravis Disease Drugs Companies by Revenue (US$ Million) in 2022 Table 20. Global 5 Largest Players Market Share by Myasthenia Gravis Disease Drugs Revenue (CR5 and HHI) & (2018-2023) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Myasthenia Gravis Disease Drugs Product Solution and Service Table 23. Date of Enter into Myasthenia Gravis Disease Drugs Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Myasthenia Gravis Disease Drugs Market Size by Type (2018-2023) & (US$ Million) Table 26. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Type (2018-2023) Table 27. Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million) Table 28. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Type (2024-2029) Table 29. Global Myasthenia Gravis Disease Drugs Market Size by Application (2018-2023) & (US$ Million) Table 30. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Application (2018-2023) Table 31. Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million) Table 32. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Application (2024-2029) Table 33. North America Myasthenia Gravis Disease Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 34. North America Myasthenia Gravis Disease Drugs Market Size by Country (2018-2023) & (US$ Million) Table 35. North America Myasthenia Gravis Disease Drugs Market Size by Country (2024-2029) & (US$ Million) Table 36. Europe Myasthenia Gravis Disease Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 37. Europe Myasthenia Gravis Disease Drugs Market Size by Country (2018-2023) & (US$ Million) Table 38. Europe Myasthenia Gravis Disease Drugs Market Size by Country (2024-2029) & (US$ Million) Table 39. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029 Table 40. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Region (2018-2023) & (US$ Million) Table 41. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Region (2024-2029) & (US$ Million) Table 42. Latin America Myasthenia Gravis Disease Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 43. Latin America Myasthenia Gravis Disease Drugs Market Size by Country (2018-2023) & (US$ Million) Table 44. Latin America Myasthenia Gravis Disease Drugs Market Size by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 46. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Country (2018-2023) & (US$ Million) Table 47. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Country (2024-2029) & (US$ Million) Table 48. GlaxoSmithKline Company Detail Table 49. GlaxoSmithKline Business Overview Table 50. GlaxoSmithKline Myasthenia Gravis Disease Drugs Product Table 51. GlaxoSmithKline Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 52. GlaxoSmithKline Recent Development Table 53. Novartis Company Detail Table 54. Novartis Business Overview Table 55. Novartis Myasthenia Gravis Disease Drugs Product Table 56. Novartis Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 57. Novartis Recent Development Table 58. Teva Pharmaceutical Company Detail Table 59. Teva Pharmaceutical Business Overview Table 60. Teva Pharmaceutical Myasthenia Gravis Disease Drugs Product Table 61. Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 62. Teva Pharmaceutical Recent Development Table 63. Roche Company Detail Table 64. Roche Business Overview Table 65. Roche Myasthenia Gravis Disease Drugs Product Table 66. Roche Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 67. Roche Recent Development Table 68. Bristol-Myers Squibb Company Detail Table 69. Bristol-Myers Squibb Business Overview Table 70. Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Product Table 71. Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 72. Bristol-Myers Squibb Recent Development Table 73. Apotex Company Detail Table 74. Apotex Business Overview Table 75. Apotex Myasthenia Gravis Disease Drugs Product Table 76. Apotex Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 77. Apotex Recent Development Table 78. Cipla Company Detail Table 79. Cipla Business Overview Table 80. Cipla Myasthenia Gravis Disease Drugs Product Table 81. Cipla Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 82. Cipla Recent Development Table 83. Biogen Company Detail Table 84. Biogen Business Overview Table 85. Biogen Myasthenia Gravis Disease Drugs Product Table 86. Biogen Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 87. Biogen Recent Development Table 88. AbbVie Company Detail Table 89. AbbVie Business Overview Table 90. AbbVie Myasthenia Gravis Disease Drugs Product Table 91. AbbVie Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 92. AbbVie Recent Development Table 93. Bausch Health Company Detail Table 94. Bausch Health Business Overview Table 95. Bausch Health Myasthenia Gravis Disease Drugs Product Table 96. Bausch Health Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 97. Bausch Health Recent Development Table 98. Sun Pharmaceuticals Company Detail Table 99. Sun Pharmaceuticals Business Overview Table 100. Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Product Table 101. Sun Pharmaceuticals Revenue in Myasthenia Gravis Disease Drugs Business (2018-2023) & (US$ Million) Table 102. Sun Pharmaceuticals Recent Development Table 103. Research Programs/Design for This Report Table 104. Key Data Information from Secondary Sources Table 105. Key Data Information from Primary Sources List of Figures Figure 1. Global Myasthenia Gravis Disease Drugs Market Size Comparison by Type (2023-2029) & (US$ Million) Figure 2. Global Myasthenia Gravis Disease Drugs Market Share by Type: 2022 VS 2029 Figure 3. Acetylcholinesterase Inhibitors Features Figure 4. Immunosuppressant Drugs Features Figure 5. Steroid Features Figure 6. Others Features Figure 7. Global Myasthenia Gravis Disease Drugs Market Size Comparison by Application (2023-2029) & (US$ Million) Figure 8. Global Myasthenia Gravis Disease Drugs Market Share by Application: 2022 VS 2029 Figure 9. Hospitals Case Studies Figure 10. Clinics Case Studies Figure 11. Others Case Studies Figure 12. Myasthenia Gravis Disease Drugs Report Years Considered Figure 13. Global Myasthenia Gravis Disease Drugs Market Size (US$ Million), Year-over-Year: 2018-2029 Figure 14. Global Myasthenia Gravis Disease Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029 Figure 15. Global Myasthenia Gravis Disease Drugs Market Share by Region: 2022 VS 2029 Figure 16. Global Myasthenia Gravis Disease Drugs Market Share by Players in 2022 Figure 17. Global Top Myasthenia Gravis Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myasthenia Gravis Disease Drugs as of 2022) Figure 18. The Top 10 and 5 Players Market Share by Myasthenia Gravis Disease Drugs Revenue in 2022 Figure 19. North America Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 20. North America Myasthenia Gravis Disease Drugs Market Share by Country (2018-2029) Figure 21. United States Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 22. Canada Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 23. Europe Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 24. Europe Myasthenia Gravis Disease Drugs Market Share by Country (2018-2029) Figure 25. Germany Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 26. France Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 27. U.K. Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 28. Italy Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 29. Russia Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 30. Nordic Countries Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 31. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 32. Asia-Pacific Myasthenia Gravis Disease Drugs Market Share by Region (2018-2029) Figure 33. China Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 34. Japan Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 35. South Korea Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 36. Southeast Asia Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 37. India Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 38. Australia Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 39. Latin America Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 40. Latin America Myasthenia Gravis Disease Drugs Market Share by Country (2018-2029) Figure 41. Mexico Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 42. Brazil Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 43. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 44. Middle East & Africa Myasthenia Gravis Disease Drugs Market Share by Country (2018-2029) Figure 45. Turkey Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 46. Saudi Arabia Myasthenia Gravis Disease Drugs Market Size YoY Growth (2018-2029) & (US$ Million) Figure 47. GlaxoSmithKline Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 48. Novartis Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 49. Teva Pharmaceutical Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 50. Roche Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 51. Bristol-Myers Squibb Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 52. Apotex Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 53. Cipla Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 54. Biogen Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 55. AbbVie Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 56. Bausch Health Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 57. Sun Pharmaceuticals Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2018-2023) Figure 58. Bottom-up and Top-down Approaches for This Report Figure 59. Data Triangulation Figure 60. Key Executives Interviewed

GlaxoSmithKline Novartis Teva Pharmaceutical Roche Bristol-Myers Squibb Apotex Cipla Biogen AbbVie Bausch Health Sun Pharmaceuticals